Skip to main content


Swipe om te navigeren naar een ander artikel

01-05-2010 | Uitgave 4/2010

Quality of Life Research 4/2010

Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants

Quality of Life Research > Uitgave 4/2010
Kathleen W. Wyrwich, Reema Mody, Lois M. Larsen, Misun Lee, Neesha Harnam, Dennis A. Revicki
Belangrijke opmerkingen
TAP Pharmaceutical Products Inc., Lake Forest, IL, USA, is now a part of Takeda Pharmaceuticals North America, Inc.
Lois M. Larsen, Misun Lee—TAP Pharmaceutical Products Inc. at the time of study conduct and analysis (now a part of Takeda Pharmaceuticals North America, Inc.).


Background and aims

Valid instruments are needed to assess important patient-reported outcomes (PROs) in erosive esophagitis (EE).


Data from 4,092 patients in clinical trials to determine efficacy of dexlansoprazole MR to heal EE and maintain healed EE were used to assess the psychometric properties of the Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QOL) and the PAGI-Symptoms Severity Index (PAGI-SYM). A daily diary, gastroesophageal reflux disease (GERD) Symptoms Investigator Assessment and endoscopy results were also used in this study.


PAGI-QOL and PAGI-SYM subscales and total score internal consistency reliability estimates for both studies were acceptable (Cronbach’s alpha coefficient = 0.81−0.97). Most subscale and total scores yielded moderate-to-strong correlations with other measures reflecting signs and symptoms of EE. Some subscales were able to detect differences >1 standard error of measurement (SEM) in change scores among patients with improved heartburn frequency compared to those with stable/worsening heartburn frequency in the healing study. Those with relapsed EE demonstrated differences >1 SEM in some PAGI-QOL and PAGI-SYM subscale or total scores compared to patients who maintained their healing status.


The findings of this study support the consideration of the PAGI-QOL and PAGI-SYM in future clinical trials and in the general EE population.

Log in om toegang te krijgen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Podotherapeut Totaal

Binnen de bundel kunt u gebruik maken van boeken, tijdschriften, e-learnings, web-tv's en uitlegvideo's. BSL Podotherapeut Totaal is overal toegankelijk; via uw PC, tablet of smartphone.

Over dit artikel

Andere artikelen Uitgave 4/2010

Quality of Life Research 4/2010 Naar de uitgave